Investment Committee Summary
| Rating | HOLD |
| Internal 5-tier | HOLD |
| Classification · conviction | balance-sheet repair · low |
| Evidence | 8/8 load-bearing inputs sourced |
| Triangulated fair value | $116 (+13% vs spot · triangulated FV) |
| 12-mo scenario PWEV | $114 (+11% vs spot · 12m PWEV) |
| Next catalyst | 2026-10-29 — Quarterly earnings |
| Primary thesis-break | Companywide operating margin (segment operating profit / revenue) < 0.0205 (2 consecutive prints) |
Decision detail — rating tables & Research OS strip
Rating: HOLD
Internal 5-tier: HOLD · balance-sheet repair · analyst conviction: low
| Metric | Value |
|---|---|
| Current Price | $103 |
| Triangulated Fair Value | $116 (+13% vs spot · triangulated FV) |
| 12-mo Scenario PWEV | $114 (+11% vs spot · 12m PWEV) |
| Forward P/E | 10.7x |
| Market Cap | $20B |
| 52-Week Range | $79.11–$135 (intraday high and low over the trailing 52 weeks of the stock's own daily bars) |
EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).
Methodology: Valuation triangulated across three weighted anchors — a scenario-weighted PWEV, a Monte Carlo median (Student-t + regime switching) and a peer P/E re-rate. Anchors are blended at fixed declared weights, each counted separately; the Monte Carlo and the scenario PWEV all rest on the same base multiple, so where they agree it is partly by construction — not independent corroboration. Figures reconciled to Alpha Vantage 2026-10-09. Each chart below sits with the part of the thesis it evidences.
General research, published identically to every reader. Not personal financial advice. Figures as of the analysis date; verify before acting.
Decision Support — Research OS jump to detail ↓
| Research conviction | Exp. return (1y) | Rules stance | Next catalyst |
|---|---|---|---|
| 39.4/100 (3rd pct) | +13% 1yr expected | Hold | 17d — Quarterly earnings |
Full breakdown — conviction components, probability-return distribution, decision rules, factor & portfolio interaction and the catalyst timeline — in the Decision Support sections below. Model output for research; not personal financial advice.
📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.
Recommendation: HOLD
Balanced: triangulated fair value $116 (+13% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin — a fundamental call.
Investment Thesis
At $103 (12 October 2026) Bunge trades on 11x forward earnings, below the agribusiness peer median. The market is pricing mid-cycle crush and merchandising margins on the enlarged post-Viterra revenue base, with a visible discount for net debt of ~$14.6B and unproven integration. The engine broadly shares that caution rather than disputing it. Probability-weighting the tree gives $114, and the triangulated fair value lands at $116, or +13% against the current price, leaving the shares trading cheap to that estimate. Well over a third of the scenario weight sits in the margin-reset and cyclical-trough states. The capex-bridge discounted cash flow anchors far below the market price — the engine flags that divergence from the simulated median explicitly rather than burying it — because razor-thin processing margins leave very little free cash after a heavy capital programme. The equity case therefore rests on the multiple and on the cycle, not on cash generation, and that is the load-bearing assumption. HOLD follows. The single most damaging risk is a structural reset in crush economics, whose scenario target sits well below the 52-week low.
Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.
The dashboard below is the whole argument on one page: spot ($103) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The bear mechanism is a structural reset in global crush economics, not a soft quarter. Soybean crush capacity added for renewable diesel in North America and processing expansion in Brazil keeps running even if biofuel policy support fades; meal and oil supply then outpaces demand and crush margins settle structurally lower. Bunge earns only a sliver of operating profit per revenue dollar, so a modest margin reset removes a large share of earnings — the operating leverage that flatters an upcycle is symmetric on the way down. Viterra adds merchandising volume, not margin, and net debt of ~$14.6B taken to fund the combination restricts repurchases precisely when earnings compress. On that path the multiple compresses onto trough earnings and the structural target lands below the 52-week low. It carries the heaviest weight of any downside state, which is the point: this is the cycle's floor, not a tail sketch.
Key Debate
Gross Margin explains 54% of Monte Carlo outcome variance — the single variable that decides which side is right.
What the Market Is Pricing In
At the current price, the market pays 10.8× consensus forward EPS, vs the house DCF terminal 10.0×, and a peer median 14.8×. The house DCF sits 76% below spot, so the market is pricing in more than the house case — roughly 2.1pp of revenue CAGR.
Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.
| Metric | Consensus | House | Importance |
|---|---|---|---|
| Revenue | 91.7 | 82.2 | High |
| EPS | 9.6 | 9.6 | Medium |
| Target price | 141.8 | 113.7 | Medium |
Scenario Analysis
The scenario tree spans a structural 'Structural — Crush / Protein Margin Reset' downside ($40.40) to a 'Spike — Supply Dislocation' bull case ($242); the probability-weighted blend (PWEV $114) is +11% versus spot.
| Scenario | Probability | Target | Return vs spot |
|---|---|---|---|
| Structural — Crush / Protein Margin Reset | 22% | $40.40 | -61% |
| Cyclical Margin Trough | 18% | $69.20 | -33% |
| Base — Mid-Cycle Crush / Protein Margins | 32% | $116 | +13% |
| Upcycle — Tight Margins | 20% | $190 | +85% |
| Spike — Supply Dislocation | 8% | $242 | +135% |
| Probability-Weighted (PWEV, after SBC dilution) | — | $114 | +11% |
SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (1.5% of shares, on SBC ≈ 0% of revenue), trimming the gross PWEV of $116 to $114 (-1.5%). SBC is charged once, as dilution — never also deducted from FCF.
Scenario rationale — the driver path behind every target:
- Structural — Crush / Protein Margin Reset (22%, $40.40). Structural impairment — crush / protein margin reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
- Cyclical Margin Trough (18%, $69.20). Cyclical downturn — ag-processing crush margins / protein cycle + commodity & feed costs weakens for 1–2 years before normalising.
- Base — Mid-Cycle Crush / Protein Margins (32%, $116). Mid-cycle — normalised ag-processing crush margins / protein cycle + commodity & feed costs; disciplined capital allocation; steady returns.
- Upcycle — Tight Margins (20%, $190). Upside — tight crush / protein margins lifts earnings above mid-cycle; the multiple expands modestly.
- Spike — Supply Dislocation (8%, $242). Upside tail — sustained tight conditions or a structural re-rate on tight crush / protein margins.
Valuation Triangulation
Three weighted anchors — a scenario-weighted pwev, a monte carlo median (student-t + regime switching) and a peer p/e re-rate — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat three numbers as three independent votes.
| Method | Basis | Fair Value | vs Spot | Weight in this name's blend |
|---|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $102 | -1% | 30% (declared 15%) |
| Peer P/E re-rate | multiple | $142 | +38% | 20% (declared 10%) |
| Peer EV/Revenue re-rate | multiple | $348 | +239% | 0% — cross-check only |
| Scenario PWEV | multiple | $114 | +11% | 50% (declared 25%) |
| DCF (5-year + exit-multiple terminal) | cash flow + terminal × | $24.29 | -76% | 0% — excluded |
| Triangulated (weighted) | — | $116 | +13% | 100% |
The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts is not computed, so 15% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.
Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.
DCF excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.
Monte Carlo — the outcome distribution
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $102 and 49% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (54% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — explicit-period cash flows with an exit-multiple terminal
A 5-year cash-flow path discounted at a WACC of 9.0%, plus a terminal value of final-year FCF × 10.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $24.29. The terminal value is 64% of enterprise value, so this anchor moves with the multiple assumption. Excluded from the weighted blend as an outlier — shown as a cross-check; its exit-multiple terminal means it is not independent of the multiple-driven anchors.
Peer benchmarking — relative value
Against its 3 peers in the same GICS sub-industry, re-rating to their median forward multiple (P/E 14.8x) implies $142. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 20% so market sentiment does not set the fair value.
Across all anchors the spread is 283% of the median — wide (genuine disagreement — the blend carries low valuation confidence).
Sensitivity
DCF/share — WACC × terminal multiple
| WACC \ Term× | 7.0x | 8.5x | 10.0x | 11.5x | 13.0x |
|---|---|---|---|---|---|
| 7.0% | $11.49 | $21.95 | $32.42 | $42.88 | $53.34 |
| 8.0% | $8.27 | $18.26 | $28.25 | $38.23 | $48.22 |
| 9.0% | $5.22 | $14.75 | $24.29 | $33.83 | $43.36 |
| 10.0% | $2.31 | $11.42 | $20.53 | $29.65 | $38.76 |
| 11.0% | $-0.45 | $8.26 | $16.97 | $25.67 | $34.38 |
DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)
| CAGRΔ \ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $-82.40 | $-35.34 | $11.72 | $58.78 | $106 |
| -1.5pp | $-82.40 | $-32.28 | $17.83 | $67.95 | $118 |
| +0.0pp | $-82.40 | $-29.06 | $24.29 | $77.64 | $131 |
| +1.5pp | $-82.41 | $-25.65 | $31.11 | $87.86 | $145 |
| +3.0pp | $-82.41 | $-22.06 | $38.29 | $98.64 | $159 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Model op margin ±3pp | $-82.00 | $131 | $213 |
| Capex intensity ±15% | $8.00 | $41.00 | $33.00 |
| Revenue CAGR ±3pp | $12.00 | $38.00 | $27.00 |
| Terminal × ±15% | $15.00 | $34.00 | $19.00 |
| WACC ±1pp | $21.00 | $28.00 | $8.00 |
Company lever — value at the base multiple vs Agricultural Products & Protein multiple (base 15.0x)
| Multiple | 10.5x | 12.8x | 15.0x | 17.2x | 19.5x |
|---|---|---|---|---|---|
| Value at the base multiple (EBIT × multiple; illustrative, not a blend anchor) | $-53.00 | $-49.00 | $-44.00 | $-40.00 | $-35.00 |
Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.
Peer Quality & Weighting
| Peer | Fwd P/E | Growth | Op margin | Quality | Weight cap |
|---|---|---|---|---|---|
| ADM | 16.6× | 2% | 1% | segment | 50% |
| DAR | 14.8× | 2% | 8% | segment | 50% |
| INGR | 9.4× | 2% | 12% | direct | 100% |
Quality-weighted forward P/E: 12.6× (simple median 14.8×). Direct peers count 100%, segment 50%, broad 25%.
Valuation-anchor screen: DCF (exit) (excluded (>3× or <0.3× spot)). Anchor median 101.6. Extreme/excluded anchors carry no headline weight.
Historical-range cross-check: 52-week range $79.11–$135, centre $103 (+0% vs spot); spot sits at the 42nd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.
Risk / Reward & Margin of Safety
| Metric | Value |
|---|---|
| Upside to triangulated FV (FV ÷ price − 1) | $116 (+13% vs spot · triangulated FV) |
| Downside to lowest scenario (Structural — Crush / Protein Margin Reset) | $40.40 (-61% vs spot · bear scenario) |
| Reward/risk ratio | 0.2× |
| Discount to fair value (1 − price ÷ FV) | +11% |
| P(price > spot) — Monte Carlo | 49% |
Reward/risk = (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Crush / Protein Margin Reset' target ÷ price). 'Structural — Crush / Protein Margin Reset' ($40.40, probability 22%) is the lowest-target scenario in the tree, taken gross of SBC dilution. Bull case (Spike — Supply Dislocation): $242.
Company Overview & Business Model
Bunge Global SA — CONSUMER DEFENSIVE · FARM PRODUCTS. Bunge Limited is a global food and agribusiness company. The company is headquartered in St. Louis, Missouri.
Company description as supplied by Alpha Vantage; not checked against the company's filings.
How it makes money.
| Segment | Rev mix | Growth | Model op margin† | Key driver |
|---|---|---|---|---|
| Agricultural Products & Protein | 100% | +2% | 0% | ag-processing crush margins / protein cycle + commodity & feed costs |
† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.
Reported operating margin (GAAP): 1.8% for the fiscal year ended 2025-12-31; 2.3% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).
Edge. Narrow moat. Authored moat rationale withheld pending re-authoring.
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Model op margin† | Model EBIT | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|---|
| Agricultural Products & Protein | $80.5B | 100% | 2% | 0% | $0.4B | 15.0x | 6% | ESTIMATE |
| † Model EBIT = revenue × the model margin, i.e. gross margin less the opex ratio the calibration solved for to meet the EPS target — not the company's reported operating income. |
For comparison, the company's reported GAAP operating margin was 1.8% for the fiscal year ended 2025-12-31; 2.3% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | ag-processing crush margins / protein cycle + commodity & feed costs |
| net_debt_or_cash_b | -14.59 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.06 |
| div_yield | 0.0259 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | crush / protein margin reset |
| upside | tight crush / protein margins |
Balance Sheet & Liquidity
| Metric | Value |
|---|---|
| Net debt | $13.7B — highly levered |
| Net debt / EBITDA | 4.37x |
| Interest coverage (EBIT / interest) | 2.8x |
| Current ratio | 1.61x |
| Lease obligations | $1.6B |
| Cash & ST investments | $2.2B |
Balance-sheet data as of 2025-12-31 (Alpha Vantage).
Capital Allocation
| Metric | Value |
|---|---|
| Free cash flow | $-0.9B |
| Buybacks / dividends | $0.6B / $0.5B |
| Total shareholder yield | 5.0% |
| Payout as % of FCF | -114.9% |
| Reinvestment (capex / OCF) | 204.1% |
| SBC as % of FCF | -8.3% |
| Allocation stance | reinvesting |
Free-Cash-Flow Quality
| Metric | Value |
|---|---|
| FCF margin | -1.1% |
| FCF conversion (FCF / net income) | -104.3% |
| FCF yield | -4.4% |
| Capex intensity (capex / revenue) | 2.1% |
| FCF − SBC (diagnostic) | $-0.9B |
| Capex split (maint / growth) | 60% / 40% — Asset-heavy processor but capex runs |
Accounting quality: SBC 0% of revenue.
Competitive Moat
Moat sources:
- Global grain origination, storage and logistics network (asset footprint hard to replicate)
- Post-Viterra merchandising scale and information advantage in trading flows
- Integrated crush capacity across North America and Brazil
- No pricing-power moat — meal/oil prices are set by global supply-demand; crush margins are cyclical and mean-reverting
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q2): management +0.33 vs analyst floor +0.00 → delta +0.33 (n=31 mgmt / 18 Q&A; 32nd pctile across the S&P book, z -0.6).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q2 | +0.33 | +0.00 | +0.33 |
| 2026Q1 | +0.23 | +0.08 | +0.15 |
| 2025Q4 | +0.45 | +0.26 | +0.20 |
| 2025Q3 | +0.48 | +0.21 | +0.27 |
News (last 365d, 1300 articles): avg ticker sentiment +0.19 (bullish 27% / bearish 4%)
Consensus & Market Expectations
| Reference | Value |
|---|---|
| Street target (mean) | $142 (+38% vs spot · street) |
| House target | $114 (-19.8% vs street) |
| Sell-side coverage | 9 analysts (SB 3 / B 5 / H 1 / S 0 / SS 0; net score 0.61) |
| Consensus FY EPS | $9.55 (reference only — house values on EV/EBITDA) |
| Consensus FY revenue | $91.7B; house below (-10.4%) |
_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.
Catalyst Calendar
- 2026-10-29 (~20d) — Quarterly earnings — est. EPS $2.45 (AV EARNINGS_CALENDAR)
- 2026-11-04 (~26d) — FY2026 adjusted-EPS guidance at Q3 earnings (authored)
- 2027-01-31 (~114d) — US EPA biofuel blending / renewable-diesel mandate (RVO) decision (authored)
Forecast Track Record
- EPS surprise: beat 75% of the last 8 quarters; average surprise +22.6%.
Catalyst Timeline
6 catalysts in the next 90 days (of 14 tracked). Importance 1–3; confidence 0–1.
| When | Catalyst | Type | Importance | Confidence |
|---|---|---|---|---|
| 2026-10-14 (in 2d) | September CPI | macro | ●● | 0.8 |
| 2026-10-28 (in 16d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2026-10-29 (in 17d) | Quarterly earnings | earnings | ●●● | 0.95 |
| 2026-11-04 (in 23d) | FY2026 adjusted-EPS guidance at Q3 earnings | earnings | ●●● | 0.95 |
| 2026-12-09 (in 58d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2026-12-18 (in 67d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-01-27 (in 107d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-01-31 (in 111d) | US EPA biofuel blending / renewable-diesel mandate (RVO) decision | authored | ● | 0.7 |
| 2027-03-17 (in 156d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-03-19 (in 158d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-04-28 (in 198d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-06-09 (in 240d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-06-18 (in 249d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-09-17 (in 340d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
_Sources: extended.catalysts, data/catalysts/
Regulatory & Legal Risk
| Issue | Probability | Valuation sensitivity | Horizon |
|---|---|---|---|
| US renewable-diesel / biofuel policy (RVO mandates) softening soybean-oil crush demand | medium (~40%) | high - crush margin is the earnings driver; a policy-driven reset compresses FV materially, ~10-15% of FV | 12-24m |
| Antitrust/regulatory integration conditions and remedies on the Viterra combination | low (~20%) | medium - forced divestitures dilute the merchandising-scale thesis, ~5% of FV | 12-24m |
Probabilities and sensitivities are analyst estimates, not market-implied.
Scenario Macro & Key Risks
| Scenario | Macro assumption | Key risk |
|---|---|---|
| Cyclical Margin Trough | Crush and protein margins weaken for 1-2 years on oversupply or weak demand before normalising. | The trough persists and the market re-prices it as the structural reset. |
| Base — Mid-Cycle Crush / Protein Margins | Normalised crush and merchandising margins on the enlarged post-Viterra revenue base with disciplined capital allocation. | Viterra adds volume not margin, so the enlarged base dilutes rather than lifts returns. |
| Upcycle — Tight Margins | Crush spreads run above mid-cycle with Viterra merchandising capturing price volatility; modest multiple step-up. | Tight margins prove short-lived as new capacity comes online and competes the spread away. |
| Spike — Supply Dislocation | A weather or geopolitical shock keeps crush and trading margins near prior-peak levels; premium carried mostly in earnings. | The spike is transitory and mean-reverts sharply once the dislocation resolves, stranding peak-cycle expectations. |
Scenario-macro rows withheld pending re-authoring: 1 carrying another cluster's vocabulary or a frozen figure — recorded in the narrative quarantine ledger.
Decision Rules (Machine-Checked)
Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 5 evaluable (1 lacked data).
| Rule | Condition | Observed | Triggered |
|---|---|---|---|
| R1-valuation-stretch | expected return vs fair value < -12 (upside_pct) |
10.65 | no |
| R2-valuation-opportunity | expected return vs fair value > 15 (upside_pct) |
10.65 | no |
| R3-street-revisions | street net rating stance < -0.25 (extended.consensus.street_score) |
0.61 | no |
| R4-earnings-quality | cash conversion of earnings < 80 (extended.accounting_quality.cash_conversion_pct) |
no data | — |
| R5-technical-breakdown | price vs 200-day SMA < 0.85 (technicals.sma_200) |
0.89 | no |
| R6-vol-regime-shift | IV/RV vol-risk premium > 1.4 (options_overlay.iv_rv) |
1.15 | no |
Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.
Reasons the Thesis Could Fail (Falsifiable)
Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:
- Companywide operating margin (segment operating profit / revenue) < 0.0205 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
- Full-year adjusted EPS guidance ($) < 6.75 (single event). 6.75 is the midpoint of the base-scenario EPS (~7.75, consistent with the ~13.9x forward multiple at spot) and the trough EPS (~5.77). A guidance cut below that line is management conceding the crush cycle has rolled over before Viterra synergies land.
- Revenue growth (YoY) < -0.005 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
- Net debt ($B) > 17.0 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
- Annual capital expenditure ($B) > 2.6 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
Fact / Inference / Speculation
- FACT: Spot $103; 52-week range $79.11–$135; engine rating HOLD; house target $114 (+11%). (source: Alpha Vantage 2026-10-09, 12 October 2026)
- INFERENCE: Triangulated FV $116 (+13% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
- SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.
Conviction Score
Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.
39.4/100 (confidence band 26.1–52.8), 3rd percentile of 893 covered names (as of 2026-10-10). Weighted composite under config ros-1.20.0 — every component and its inputs below.
| Component | Score (0–100) | Weight | Inputs |
|---|---|---|---|
| business quality | 15 | 15% | extended.fcf_quality.fcf_margin_pct, extended.balance_sheet.net_debt_to_ebitda, extended.accounting_quality.cash_conversion_pct |
| financial strength | 12 | 10% | extended.balance_sheet.net_debt_to_ebitda, extended.balance_sheet.interest_coverage |
| valuation | 61 | 15% | upside_pct |
| growth | 45 | 10% | reconciliation.ttm_revenue_billions, reconciliation.fy_guide_revenue_billions |
| earnings visibility | 75 | 10% | extended.forecast_accuracy.eps_surprise.beat_rate_pct |
| moat | 45 | 10% | enrichment.moat.rating |
| technical trend (heuristic — no validation record; weight change reserved for AM-060) | 20 | 10% | technicals.rsi, technicals.sma_50, technicals.sma_200 |
| macro tailwinds | — | 10% | industry_context.house |
| risk profile | 45 | 10% | monte_carlo.prob_above_current, monte_carlo.p10, monte_carlo.p90, monte_carlo.median |
Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.
Score history: 37.1 → 37.4 → 37.2 → 37.3 → 38.3 → 38.3 → 38.5 → 39.6.
Probability-Weighted Return Profile
Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.
| Scenario | Probability | Target | Total return | Contribution |
|---|---|---|---|---|
| Structural — Crush / Protein Margin Reset | 22% | $40.40 | -60.7% | -13.3pp |
| Cyclical Margin Trough | 18% | $69.20 | -32.6% | -5.9pp |
| Base — Mid-Cycle Crush / Protein Margins | 32% | $116 | +13.1% | +4.2pp |
| Upcycle — Tight Margins | 20% | $190 | +85.3% | +17.1pp |
| Spike — Supply Dislocation | 8% | $242 | +135.5% | +10.8pp |
| Aggregate | Value |
|---|---|
| Expected return (gross, 1y) | +12.9% |
| Expected return net of SBC dilution | +11.2% |
| Outcome dispersion (σ, from MC p10–p90) | 69.0% |
| Expected Sharpe (rf 4%) | 0.13 |
| Downside expectation (prob-weighted loss branches) | -19.2% |
The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.
Expected Alpha
Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).
| Component | Value |
|---|---|
| Expected return (gross, 1y) | 12.9% |
| Risk-free rate | 4.49% (1y proxy (3m/2y midpoint; AV lacks a 1y tenor), as of 2026-10-08) |
| Beta (shrunk, 1y vs SPY) | 0.30 (as of 2026-10-09) |
| Equity risk premium | 4.5% |
| Required return | 5.8% |
| Expected alpha | +7.1% |
| Alpha per unit risk (EA/σ) | +0.10 |
A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.
Probability Cross-Checks
Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.
| Cross-check | Ours | Comparator | Reading |
|---|---|---|---|
| Scenario spread vs options market | 61.8% (1σ) | 30.4% implied | broadly consistent with the market's implied uncertainty |
| Mass above spot: scenarios vs our own MC | 60.0% | 49.4% | the two expressions of our own view agree |
| Realised scenario frequency | 58 dated anchors | — | 58 dated anchors available; realised-vs-prior comparison is now meaningful. |
Authored set: 5 scenarios, probabilities summing to 1.0, mean target $115.96.
Factor Exposures
Cross-sectional percentiles over 928 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.
| Style | Percentile | Theme | Percentile | |
|---|---|---|---|---|
| Growth | 28 | AI | 29 | |
| Value | 93 | Cloud | 6 | |
| Quality | 5 | Semis | 39 | |
| Momentum | 93 | Consumer | 3 | |
| Low-Vol | 27 | Rates | 4 | |
| USD | 62 | |||
| Energy | 96 |
Market interaction: correlation vs SPY +0.14, vs QQQ +0.07 (trailing ~1y daily returns).
Rating Bridge
Rating = HOLD because:
- Probability-weighted scenario value implies +11% vs spot
- Monte Carlo median implies -1% vs spot
- DCF fair value (exit-multiple terminal) implies -76% vs spot — but this is terminal-value sensitive (exit-multiple $24.29 vs Gordon $60.97, 151% apart), so it carries less weight
- Bear case (Structural — Crush / Protein Margin Reset) downside is -61% vs spot
- Net: reward/risk of 0.2× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.
Model Appendix
DCF — line items
| Year | Revenue | Op income (house path) | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $82B | $2B | $2B | $2B | $2B | $2B |
| FY+2 | $84B | $3B | $2B | $2B | $2B | $1B |
| FY+3 | $85B | $3B | $2B | $2B | $2B | $1B |
| FY+4 | $85B | $3B | $2B | $2B | $2B | $1B |
| FY+5 | $86B | $3B | $2B | $2B | $2B | $1B |
| Terminal | — | — | — | — | $2B × 10.0x | $12B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 6% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 9.0% · Σ PV(FCF) $7B + PV(terminal) $12B = EV $19B; − net debt $14.6B → equity $5B ÷ diluted shares $0.20B = $24.29/share (exit-multiple terminal).
- Gordon terminal → $60.97/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
- Incremental ROIC on the forecast capex ≈ 2% vs WACC 9.0% → below WACC — the incremental build is value-dilutive.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| ADM | 0.6x | 16.6x | 2% | 1% |
| DAR | 2.3x | 14.8x | 2% | 8% |
| INGR | 1.0x | 9.4x | 2% | 12% |
| Median | 1.0x | 14.8x | — | — |
Implied prices at the peer medians: same-sub-industry median fwd P/E → $142; EV/Rev → $348.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| Scenario PWEV | $114 | 50% | $57.12 |
| Monte Carlo median | $102 | 30% | $30.48 |
| Peer P/E | $142 | 20% | $28.40 |
| Triangulated | — | 100% | $116 |
Model Calibration Caveats
Raised by the model's own checks on its run of 12 October 2026 (prices as of 2026-10-09). They concern how the model was calibrated, not the company; read the figures they touch with them in mind.
- The DCF ($24) and the Monte Carlo median ($102) are 76% apart — the two methods disagree materially on these inputs.
Assumption Register
| Assumption | Value | Used in | Source |
|---|---|---|---|
| WACC | 9.0% | DCF discount rate | estimate (CAPM) |
| Terminal multiple | 10× | DCF exit value | house rule (0.85 × base multiple) |
| Terminal growth | 2.5% | Gordon cross-check (single point) | estimate |
| SBC dilution | 1.5%/yr | PWEV, MC, DCF (charged once) | estimate (from SBC/rev) |
| EPS basis | consensus forward EPS (broker-adjusted, non-GAAP) | all forward P/E & scenario multiples | definition |
Sensitivity-ranked drivers (widest fair-value swing first): Model op margin ±3pp (213.0); Capex intensity ±15% (33.0); Revenue CAGR ±3pp (27.0); Terminal × ±15% (19.0); WACC ±1pp (8.0).
Inputs, Sources & Confidence
Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)
| Input | Value | Type | Source | Confidence | Used in |
|---|---|---|---|---|---|
| Revenue TTM | $80.5B | reported fact | 10-K/10-Q via AV | High | Forecast base, EV/Rev |
| FY+1 guided revenue | $82.2B | company guidance | Company guidance | Medium | Forecast, SoP |
| FY+1 guided EPS | $9.6149 | company guidance | Company guidance | Medium | Forward P/E, scenarios |
| Consensus FY EPS | $9.5542 | consensus estimate | Sell-side consensus via AV | Medium | Variant perception |
| Diluted shares | 0.195B | reported fact | 10-K via AV | High | Market cap, per-share |
| Net debt / cash | $13.651B | reported fact | Balance sheet via AV | High | EV, DCF equity bridge |
| WACC | 9.0% | house estimate | CAPM (beta/rf) | Medium | DCF discount rate |
| Terminal multiple | 10× | house estimate | House rule: 0.85 × the base multiple (shared with the Monte Carlo) | Medium | DCF exit value |
| Terminal growth | 2.5% | house estimate | Long-run GDP+ | Medium | Gordon cross-check (single point, not in the blend) |
| SBC dilution | 1.5%/yr | house estimate | From SBC/revenue | Medium | PWEV, MC, DCF (charged once) |
Research Provenance
| Field | Value |
|---|---|
| Quantitative engine | mch_stock_engine v2.0 |
| Research OS config | ros-1.20.0 |
| Analysis as-of | 2026-10-12 (prices 2026-10-09) |
| Narrative authorship | claude-opus-5 · Claude Code, supervised, drafted 2026-08-16 |
| Human review | Marinus 2026-08-16 |
| Evidence | 8/8 load-bearing inputs sourced; 13/14 mandated claims cited |
| QA | scanned post-emit by the document-QA layer; the publication label (Draft / Research / Decision-level) is stamped on the published page, not authored here |
Load-Bearing Assumptions
DCF: WACC 9.0%, terminal multiple 10×, FY+5 revenue $86B. Triangulation leans 50% on PWEV, 30% on the Monte Carlo median, 20% on peer-implied value.
Appendix & audit trail — source log, data provenance, disclosures
Source Log
| Source | Type | Date | Used for | Reference |
|---|---|---|---|---|
| Alpha Vantage — GLOBAL_QUOTE / OVERVIEW | market data | 2026-10-09 | Price, market cap, EV, forward P/E | Alpha Vantage 2026-10-09 |
| MCH engine — trailing 52 weeks of daily bars | derived | 2026-10-09 | 52-week range (intraday high and low over the trailing year of the stock's own daily bars) | trailing 52 weeks of own daily bars (intraday high/low, 2025-10-10 to 2026-10-09, 251 sessions) |
| Company income statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-09 | Revenue, gross/operating margin, EBIT, interest expense | INCOME_STATEMENT / latest annual |
| Company balance sheet (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-09 | Cash, debt, net debt, leases, equity, coverage | BALANCE_SHEET / latest annual |
| Company cash-flow statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-09 | Operating cash flow, capex, FCF, buybacks, dividends, SBC | CASH_FLOW / latest annual |
| Company earnings releases via Alpha Vantage | reported fact | 2026-10-09 | Reported EPS, surprise history | EARNINGS / quarterly |
| Sell-side consensus via Alpha Vantage | consensus estimate | 2026-10-09 | Forward revenue/EPS consensus, analyst count | EARNINGS_ESTIMATES |
| Earnings calendar via Alpha Vantage | market data | 2026-10-09 | Next earnings date, catalyst timing | EARNINGS_CALENDAR |
| Company guidance | company guidance | 2026-10-09 | FY guided revenue / non-GAAP EPS basis | company guidance / earnings call |
| MCH segment model (from filings & disclosures) | house estimate | 2026-10-09 | Segment revenue and multiple; model margin = gross margin − the calibrated opex ratio (not a reported margin) | company_context (authored, tagged) |
| MCH qualitative analysis | inference | 2026-10-09 | Moat, regulatory risk, scenario macro, catalysts | company_context enrichment (authored) |
| MCH investment thesis & falsification triggers | house estimate | 2026-10-09 | Thesis, anti-thesis, thesis-break signals | authored §5.3 |
Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.
Data Sources
- Prices, fundamentals, options chain, earnings — Alpha Vantage.
- Company filings (10-K / 10-Q) — SEC filings via EDGAR.
Disclosures & Limitations
This report is for informational and research purposes only. It is not personal financial advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.
- This report is produced by the MCH Analysis quantitative research engine — valuation, scenarios, Monte Carlo and the decision layer are generated systematically from the disclosed inputs and the archetype/industry driver sets, and reviewed rather than written name-by-name. Every figure reconciles to the appendix and every score exposes its inputs.
- No suitability assessment has been performed for any individual.
- Market data may be delayed or inaccurate; figures are as of the analysis date.
- Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
- Forecasts are uncertain; past performance is not indicative of future returns.
- The author or publisher may hold positions in securities mentioned.
- Users should verify information against primary sources (company filings) before acting.
- Investing involves risk of loss; there is no guarantee any target price is achieved.
- Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.